Fibroblast growth factor receptor 1 overexpression is associated with poor survival in patients with resected muscle invasive urothelial carcinoma

Seungtaek Lim, Myoung Ju Koh, Hyeon Joo Jeong, Nam Hoon Cho, Young Deuk Choi, Do Yeun Cho, Hoi Young Lee, Sun Young Rha

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Purpose: To examine the usefulness of various receptor tyrosine kinase expressions as prognostic markers and therapeutic targets in muscle invasive urothelial cancer (UC) patients. Materials and Methods: We retrospectively analyzed the data of 98 patients with muscle invasive UC who underwent radical cystectomy between 2005 and 2010 in Yonsei Cancer Center. Using formalin fixed paraffin embedded tissues of primary tumors, immunohistochemical staining was done for human epidermal growth factor receptor 2 (HER2), fibroblast growth factor receptor 1 (FGFR1), and fibroblast growth factor receptor 3 (FGFR3). Results: There were 41 (41.8%), 44 (44.9%), and 14 (14.2%) patients who have over-expressed HER2, FGFR1, and FGFR3, respectively. In univariate analysis, significantly shorter median time to recurrence (TTR) (12.9 months vs. 49.0 months; p=0.008) and overall survival (OS) (22.3 months vs. 52.7 months; p=0.006) was found in patients with FGFR1 overexpression. By contrast, there was no difference in TTR or OS according to the HER2 and FGFR3 expression status. FGFR1 remained as a significant prognostic factor for OS with hazard ratio of 2.23 (95% confidence interval: 1.27–3.90, p=0.006) in multivariate analysis. Conclusion: Our result showed that FGFR1 expression, but not FGFR3, is an adverse prognostic factor in muscle invasive UC patients after radical cystectomy. FGFR1 might be feasible for prognosis prediction and a potential therapeutic target after thorough validation in muscle invasive UC.

Original languageEnglish
Pages (from-to)831-839
Number of pages9
JournalYonsei medical journal
Volume57
Issue number4
DOIs
Publication statusPublished - 2016 Jul

Fingerprint

Receptor, Fibroblast Growth Factor, Type 1
Receptor, Fibroblast Growth Factor, Type 3
Carcinoma
Muscles
Survival
Neoplasms
Cystectomy
Recurrence
Receptor Protein-Tyrosine Kinases
Paraffin
Formaldehyde
Multivariate Analysis
Confidence Intervals
Staining and Labeling
Therapeutics

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

@article{1c3b8e498ece4df9a77aae14d4583111,
title = "Fibroblast growth factor receptor 1 overexpression is associated with poor survival in patients with resected muscle invasive urothelial carcinoma",
abstract = "Purpose: To examine the usefulness of various receptor tyrosine kinase expressions as prognostic markers and therapeutic targets in muscle invasive urothelial cancer (UC) patients. Materials and Methods: We retrospectively analyzed the data of 98 patients with muscle invasive UC who underwent radical cystectomy between 2005 and 2010 in Yonsei Cancer Center. Using formalin fixed paraffin embedded tissues of primary tumors, immunohistochemical staining was done for human epidermal growth factor receptor 2 (HER2), fibroblast growth factor receptor 1 (FGFR1), and fibroblast growth factor receptor 3 (FGFR3). Results: There were 41 (41.8{\%}), 44 (44.9{\%}), and 14 (14.2{\%}) patients who have over-expressed HER2, FGFR1, and FGFR3, respectively. In univariate analysis, significantly shorter median time to recurrence (TTR) (12.9 months vs. 49.0 months; p=0.008) and overall survival (OS) (22.3 months vs. 52.7 months; p=0.006) was found in patients with FGFR1 overexpression. By contrast, there was no difference in TTR or OS according to the HER2 and FGFR3 expression status. FGFR1 remained as a significant prognostic factor for OS with hazard ratio of 2.23 (95{\%} confidence interval: 1.27–3.90, p=0.006) in multivariate analysis. Conclusion: Our result showed that FGFR1 expression, but not FGFR3, is an adverse prognostic factor in muscle invasive UC patients after radical cystectomy. FGFR1 might be feasible for prognosis prediction and a potential therapeutic target after thorough validation in muscle invasive UC.",
author = "Seungtaek Lim and Koh, {Myoung Ju} and Jeong, {Hyeon Joo} and Cho, {Nam Hoon} and Choi, {Young Deuk} and Cho, {Do Yeun} and Lee, {Hoi Young} and Rha, {Sun Young}",
year = "2016",
month = "7",
doi = "10.3349/ymj.2016.57.4.831",
language = "English",
volume = "57",
pages = "831--839",
journal = "Yonsei Medical Journal",
issn = "0513-5796",
publisher = "Yonsei University College of Medicine",
number = "4",

}

Fibroblast growth factor receptor 1 overexpression is associated with poor survival in patients with resected muscle invasive urothelial carcinoma. / Lim, Seungtaek; Koh, Myoung Ju; Jeong, Hyeon Joo; Cho, Nam Hoon; Choi, Young Deuk; Cho, Do Yeun; Lee, Hoi Young; Rha, Sun Young.

In: Yonsei medical journal, Vol. 57, No. 4, 07.2016, p. 831-839.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Fibroblast growth factor receptor 1 overexpression is associated with poor survival in patients with resected muscle invasive urothelial carcinoma

AU - Lim, Seungtaek

AU - Koh, Myoung Ju

AU - Jeong, Hyeon Joo

AU - Cho, Nam Hoon

AU - Choi, Young Deuk

AU - Cho, Do Yeun

AU - Lee, Hoi Young

AU - Rha, Sun Young

PY - 2016/7

Y1 - 2016/7

N2 - Purpose: To examine the usefulness of various receptor tyrosine kinase expressions as prognostic markers and therapeutic targets in muscle invasive urothelial cancer (UC) patients. Materials and Methods: We retrospectively analyzed the data of 98 patients with muscle invasive UC who underwent radical cystectomy between 2005 and 2010 in Yonsei Cancer Center. Using formalin fixed paraffin embedded tissues of primary tumors, immunohistochemical staining was done for human epidermal growth factor receptor 2 (HER2), fibroblast growth factor receptor 1 (FGFR1), and fibroblast growth factor receptor 3 (FGFR3). Results: There were 41 (41.8%), 44 (44.9%), and 14 (14.2%) patients who have over-expressed HER2, FGFR1, and FGFR3, respectively. In univariate analysis, significantly shorter median time to recurrence (TTR) (12.9 months vs. 49.0 months; p=0.008) and overall survival (OS) (22.3 months vs. 52.7 months; p=0.006) was found in patients with FGFR1 overexpression. By contrast, there was no difference in TTR or OS according to the HER2 and FGFR3 expression status. FGFR1 remained as a significant prognostic factor for OS with hazard ratio of 2.23 (95% confidence interval: 1.27–3.90, p=0.006) in multivariate analysis. Conclusion: Our result showed that FGFR1 expression, but not FGFR3, is an adverse prognostic factor in muscle invasive UC patients after radical cystectomy. FGFR1 might be feasible for prognosis prediction and a potential therapeutic target after thorough validation in muscle invasive UC.

AB - Purpose: To examine the usefulness of various receptor tyrosine kinase expressions as prognostic markers and therapeutic targets in muscle invasive urothelial cancer (UC) patients. Materials and Methods: We retrospectively analyzed the data of 98 patients with muscle invasive UC who underwent radical cystectomy between 2005 and 2010 in Yonsei Cancer Center. Using formalin fixed paraffin embedded tissues of primary tumors, immunohistochemical staining was done for human epidermal growth factor receptor 2 (HER2), fibroblast growth factor receptor 1 (FGFR1), and fibroblast growth factor receptor 3 (FGFR3). Results: There were 41 (41.8%), 44 (44.9%), and 14 (14.2%) patients who have over-expressed HER2, FGFR1, and FGFR3, respectively. In univariate analysis, significantly shorter median time to recurrence (TTR) (12.9 months vs. 49.0 months; p=0.008) and overall survival (OS) (22.3 months vs. 52.7 months; p=0.006) was found in patients with FGFR1 overexpression. By contrast, there was no difference in TTR or OS according to the HER2 and FGFR3 expression status. FGFR1 remained as a significant prognostic factor for OS with hazard ratio of 2.23 (95% confidence interval: 1.27–3.90, p=0.006) in multivariate analysis. Conclusion: Our result showed that FGFR1 expression, but not FGFR3, is an adverse prognostic factor in muscle invasive UC patients after radical cystectomy. FGFR1 might be feasible for prognosis prediction and a potential therapeutic target after thorough validation in muscle invasive UC.

UR - http://www.scopus.com/inward/record.url?scp=84969135194&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84969135194&partnerID=8YFLogxK

U2 - 10.3349/ymj.2016.57.4.831

DO - 10.3349/ymj.2016.57.4.831

M3 - Article

C2 - 27189274

AN - SCOPUS:84969135194

VL - 57

SP - 831

EP - 839

JO - Yonsei Medical Journal

JF - Yonsei Medical Journal

SN - 0513-5796

IS - 4

ER -